立他司特(Xiidra)治疗干眼效果好不好？

Xiidra is more effective in treating dry eyes. Xiidra is a prescription drug used to treat dry eye symptoms such as dry eyes, itching, stinging, and foreign body sensation. It is a topical treatment that relieves dry eye symptoms by regulating inflammation and immune response in the eye.

Based on clinical studies, Ritalast has shown some efficacy in relieving dry eye symptoms and is considered an effective treatment option. Studies have shown that Ritalast can significantly improve eye moistness and reduce the severity of dry eye symptoms.

Treatment for dry eye disease wins FDA approval

Dry eye disease (DED) is a common eye disease that can impose a significant burden on quality of life and daily activities. Xiidra is a new inhibitor of intercellular adhesion factors that works by blocking the binding between intercellular adhesion molecule-1 and the integrin protein lymphocyte function-associated antigen-1.

In July 2016, the U.S. Food and Drug Administration (FDA) officially approved the application for 5% Litalast eye drops (trade name XiidraTM). The clinical trials of this drug mainly include one 12-week Phase II clinical trial and three 12-week Phase III clinical trials for patients with dry eye syndrome. The research results fully proved the effectiveness and safety of the drug. In clinical trials of adults with DED, Xiidra 5.0% improved the signs and symptoms of DED.

Xiidra is better for treating dry eyes

Xiidra is effective in treating dry eye disease. Xiidra is an integrin antagonist that can reduce ocular surface inflammation, thereby improving dry eye disease (DED).

Xiidra can inhibit the interaction between ICAM-1 and LFA-1. In a 12-week study, the efficacy of Xiidra 5% was compared with vehicle in patients with dry eye syndrome.

Taken together, the results of these trials support the therapeutic efficacy of Xiidra 5% in improving dry eye symptoms (i.e., change in visual analogue score of ocular dryness from baseline to day 84) and signs of dry eye (i.e., change in inferior corneal fluorescein staining score from baseline to day 84). Xiidra eye drops are generally well tolerated.

The specific effect of Xiidra on dry eye disease

Xiidra is a lymphocyte function-associated antigen-1 antagonist used to reduce inflammation in dry eye disease (DED). A Phase III study to evaluate the efficacy and safety of lifitegrast compared with placebo in patients with DED.

Design: A 12-week, randomized, double-blind, multicenter, placebo-controlled, phase III study. Participants: Adults ≥18 years of age, Schirmer tear test (without anesthesia) ≥1 and ≤10 mm, corneal fluorescein stain score ≥2.0 (0-4), Eye Dryness Score (EDS) ≥40 (0-100 visual analogue scale [VAS]), and history of artificial tear use within 30 days of study entry.

Methods: Following a 14-day placebo-controlled trial, subjects were randomized in a 1:1 ratio to receive Xiidra 5.0% or placebo twice daily for 84 days.

Main outcome measure: The primary efficacy endpoint is change from baseline to day 84 in EDS. Key secondary efficacy endpoints are changes from baseline to days 42 and 14 in EDS. Other secondary efficacy endpoints include other VAS items (burning/tingling, itching, foreign body sensation, ocular discomfort, photophobia, pain), ocular discomfort score (ODS), and the safety/tolerability of Xiidra compared with placebo.

Results: In this study, 711 participants were randomized: 356 to placebo or 355 to Xiidra (intention-to-treat [ITT] population). On Day 84, subjects who received Xiidra showed significantly greater improvements in EDS than those who received placebo. The mean change in EDS from baseline also significantly favored Xiidra on Day 42. No statistically significant differences in ODS were observed between treatment groups at days 84, 42, or 14. Greater improvements in itching, foreign body sensation, and eye discomfort were observed on Day 42 in Xiidra-treated participants compared with participants who received placebo. Most treatment-emergent events were mild to moderate in severity; no serious ocular adverse events were reported.

Conclusions: Xiidra significantly improved dry eye symptoms in patients with DED compared with placebo, as measured by EDS. Improvement in EDS was observed as early as day 14.

Summary

Xiidra is effective in treating dry eye syndrome. However, each patient's situation is different, so the effectiveness of Rituralast may vary from individual to individual. Some patients may experience significant improvement with Rituralast, while others may experience less significant improvement.

Before using Ritalast, it is recommended to consult an ophthalmologist or medical professional to understand whether this drug is suitable for your situation, and to follow the doctor's guidance and prescription.

Recommended related articles: